No phaseCompleted
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes (Liragest)
- Sponsor
- Turku University Hospital (Government)
- Enrollment
- 67 enrolled
- Conditions
- Gestational Diabetes
- Interventions
- Liraglutide 6 MG/ML [Victoza]; Placebos
- Ages
- children, adults, older adults
- Registry
- NCT04324229
Full record on ClinicalTrials.gov
From the registry
Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same laboratory tests are taken and instructions given at baseline 6 month and one year. After one year visits once a year until 5 years with same laboratory tests and measurements are taken.
Primary outcomes
- Incidence of type 2 diabetes
History
Last registry update
Primary completion
Registered
Started